Financials Revvity, Inc.

Equities

RVTY

US7140461093

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:02 2024-05-15 pm EDT			5-day change	1st Jan Change
107.3 ^USD	+0.73%		+4.36%	-1.83%

Apr. 30	TD Cowen Adjusts Price Target on Revvity to $130 From $123	MT
Apr. 30	JPMorgan Adjusts Price Target on Revvity to $105 From $100, Neutral Rating Maintained	MT

Valuation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	10,788	16,068	25,374	17,712	13,490	13,145	-	-
Enterprise Value (EV) ¹	12,670	17,657	29,739	21,652	16,476	15,529	15,159	15,367
P/E ratio	47.6 x	22.1 x	25.2 x	30.6 x	19.7 x	53.5 x	39.7 x	33.6 x
Yield	0.29%	0.2%	0.14%	-	0.26%	0.26%	0.26%	0.26%
Capitalization / Revenue	3.74 x	4.25 x	5 x	3.84 x	4.9 x	4.7 x	4.39 x	4.08 x
EV / Revenue	4.39 x	4.67 x	5.87 x	4.7 x	5.99 x	5.56 x	5.06 x	4.77 x
EV / EBITDA	19.6 x	14 x	16.2 x	15.2 x	19.7 x	18.1 x	16.2 x	14.9 x
EV / FCF	44.1 x	21.7 x	22.7 x	36.4 x	1,664 x	28.2 x	20.4 x	18.1 x
FCF Yield	2.27%	4.61%	4.41%	2.74%	0.06%	3.54%	4.89%	5.53%
Price to Book	3.85 x	4.31 x	3.55 x	-	1.73 x	1.66 x	1.59 x	1.55 x
Nbr of stocks (in thousands)	111,101	111,974	126,200	126,316	123,407	123,393	-	-
Reference price ²	97.10	143.5	201.1	140.2	109.3	106.5	106.5	106.5
Announcement Date	1/27/20	2/2/21	2/1/22	2/14/23	2/1/24	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	2,884	3,784	5,070	4,611	2,751	2,794	2,997	3,222
EBITDA ¹	645.7	1,257	1,838	1,421	836.5	856.6	938.2	1,029
EBIT ¹	596	1,203	1,771	1,381	769.9	780.7	861.9	950
Operating Margin	20.66%	31.8%	34.93%	29.95%	27.98%	27.94%	28.76%	29.49%
Earnings before Tax (EBT) ¹	237.1	906.4	1,280	-	183	337.4	452.6	562
Net income ¹	227.6	727.9	932.2	579.2	693.1	245.8	329.8	388.5
Net margin	7.89%	19.24%	18.39%	12.56%	25.19%	8.8%	11.01%	12.06%
EPS ²	2.040	6.490	7.990	4.580	5.550	1.992	2.682	3.170
Free Cash Flow ¹	287.1	814.7	1,311	594.2	9.904	550.1	741.9	849.1
FCF margin	9.95%	21.53%	25.86%	12.89%	0.36%	19.69%	24.76%	26.35%
FCF Conversion (EBITDA)	44.47%	64.8%	71.3%	41.83%	1.18%	64.22%	79.07%	82.48%
FCF Conversion (Net income)	126.18%	111.92%	140.63%	102.59%	1.43%	223.76%	224.94%	218.56%
Dividend per Share ²	0.2800	0.2800	0.2800	-	0.2800	0.2801	0.2800	0.2742
Announcement Date	1/27/20	2/2/21	2/1/22	2/14/23	2/1/24	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2
Net sales ¹	1,365	1,260	1,230	1,033	1,089	675.1	709.3	670.9	696.1	650.1	693.3	699.6	749.7	701.9	738.8
EBITDA ¹	478.2	427.2	420.4	282.6	311.9	206.4	220.5	202	207.7	182.4	208.7	213.8	248	213.1	233.6
EBIT ¹	458.7	409.8	401.9	271.7	297.8	189.2	204.3	184.6	191.8	165.8	189.2	194.4	230.9	189.8	209.4
Operating Margin	33.62%	32.53%	32.68%	26.31%	27.35%	28.03%	28.8%	27.51%	27.55%	25.5%	27.29%	27.79%	30.79%	27.04%	28.34%
Earnings before Tax (EBT) ¹	-	-	-	-	-	29.44	71.55	50.6	31.38	34.55	70.42	65.7	105.4	81.57	104.1
Net income ¹	179.2	177	179.2	85.35	137.7	569.5	35.56	9.497	78.56	26.01	62.01	60.24	96.25	63.29	82.69
Net margin	13.13%	14.05%	14.57%	8.27%	12.64%	84.36%	5.01%	1.42%	11.29%	4%	8.94%	8.61%	12.84%	9.02%	11.19%
EPS ²	1.410	1.400	1.420	0.6700	1.090	4.500	0.2800	0.0800	0.6400	0.2100	0.5000	0.4875	0.7800	0.5200	0.6750
Dividend per Share ²	0.0700	0.0700	0.0700	0.0700	-	0.0700	0.0700	-	0.0700	-	0.0700	0.0700	0.0701	0.0700	0.0700
Announcement Date	2/1/22	5/3/22	8/1/22	11/8/22	2/14/23	5/11/23	8/1/23	10/30/23	2/1/24	4/29/24	-	-	-	-	-

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	1,882	1,589	4,366	3,940	2,986	2,384	2,014	2,222
Net Cash position ¹	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	2.915 x	1.264 x	2.375 x	2.773 x	3.57 x	2.783 x	2.147 x	2.158 x
Free Cash Flow ¹	287	815	1,311	594	9.9	550	742	849
ROE (net income / shareholders' equity)	16.9%	22.2%	17.2%	13.8%	5.57%	7.43%	7.95%	8.65%
ROA (Net income/ Total Assets)	7.31%	10%	8.11%	6.9%	3.07%	4.28%	4.99%	5.93%
Assets ¹	3,115	7,274	11,488	8,392	22,588	5,741	6,613	6,548
Book Value Per Share ²	25.20	33.30	56.60	-	63.10	64.20	66.80	68.90
Cash Flow per Share ²	3.260	7.960	12.10	5.380	0.7300	6.220	5.460	6.330
Capex ¹	76.3	77.5	99.9	85.6	81.4	81.4	81.7	87.3
Capex / Sales	2.65%	2.05%	1.97%	1.86%	2.96%	2.91%	2.73%	2.71%
Announcement Date	1/27/20	2/2/21	2/1/22	2/14/23	2/1/24	-	-	-

¹USD in Million²USD

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Revvity, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

106.5 USD

Average target price

123.6 USD

Spread / Average Target

+16.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
REVVITY, INC.	-2.54%	13.15B
THERMO FISHER SCIENTIFIC	+12.06%	227B
DANAHER CORPORATION	+12.07%	192B
INTUITIVE SURGICAL, INC.	+13.88%	136B
BOSTON SCIENTIFIC CORPORATION	+27.12%	108B
SIEMENS HEALTHINEERS AG	+0.91%	64.07B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.74%	51.87B
EDWARDS LIFESCIENCES CORPORATION	+13.39%	52.1B
AGILENT TECHNOLOGIES, INC.	+8.81%	44.33B
GE HEALTHCARE TECHNOLOGIES INC.	+4.14%	36.75B

Other Advanced Medical Equipment & Technology